Opko Health Inc (NASDAQ:OPK) has today made announcement revealing the move by GeneDx to extend its relationship with the University of California Health (UC Health) for molecular, genomic and genetic testing services. GeneDx is a business unit of OPKO’s BioReference Laboratories division which over the years has exhibited remarkable performance.
UC health has also revealed its plan to settle for GeneDx which it believes to be the best choice in supplementing its own robust offering of molecular, genomic and genetic testing services. UC health has direct access to molecular oncology resources and the latest in next generation genetics both internally and externally. This has helped it maintain its top position in precision medicine.
OPKO’s GeneDx is a trusted commercial genetics laboratory operating in the United States whereas OPKO’s GenPath Oncology segment was in one of the top groups that sought out to understand the molecular nature of cancer.
The President of BioReference Laboratories, Gregory S. Henderson while addressing a press conference said: “The foundation of precision medicine is precision diagnostics, and through this relationship with OPKO’s GeneDx, our customers at UC Health will not just better understand disease, but will close the gap between data and diagnosis to help ensure good outcomes for individuals and their communities. UC Health already provides some of the best thinking in the country on the use of diagnostic tools in clinical genomics and precision medicine.”
GeneDx will be offering UC Health special and important tools that will promote some better understanding of cancer, prenatal conditions, rare diseases and most of the challenging complexities in the area of medical diagnosis. That will be made possible through the use of a comprehensive menu of genetic and genomic tests which are expected to supplement UC Health’s testing infrastructure across its wide range of medical centers at the UC Health campuses.
GeneDx’s advanced analytic tools have been highlighted by top researchers as an important differentiator which asides from providing the highest level of genetic testing will also use technology in adding insight to the findings.
The clinician focused population health tool that GeneDx has developed according to Yahoo.com will allow the end users track their data at a cohort or individual level in a compliant and protected manner.
